News & Events

Stay Up to Date with FSA

FDA Approves Semaglutide, Novo Nordisk's Once-Weekly GLP-1 for Type 2 Diabetes

Dec 07, 2017
Semaglutide, Novo Nordisk’s once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes (T2D), received FDA approval Tuesday, after beating its rival in a head-to-head trial
>> View Full Story

No Easy Answers in Study of Legal Marijuana’s Impact on Alcohol Use Recreational. Marijuana use is now legal in four states and medical marijuana in 23 states

Nov 28, 2017

>> View Full Story

To Find New Biofuel Enzymes, It Can Take a Microbial Village

Nov 14, 2017

>> View Full Story

 

View Past News & Events >>